Abstract: The present invention relates to a cathepsin K inhibitor having the structure as shown in formula (0) and/or formula (II), wherein cyanopyrimidine or a keto group as an electrophilic group is a key group to exert a good inhibitory effect on cathepsin K. Further provided are a preparation method therefor and use thereof. The provided cathepsin K inhibitor has a relatively high inhibitory effect and selectivity, and is expected to be used for treating diseases including thyroid diseases, cardiovascular diseases, bone diseases and gum diseases.

Abstract: Disclosed are a compound of formula I or a pharmaceutically acceptable salt thereof, and use thereof in regulating and controlling an EGFR tyrosine kinase activity or preventing and treating an EGFR-related disease. The EGFR inhibitor of formula I has an inhibitory activity on EGFR D770-N771 ins NPG and NPG/T790M kinases, and an inhibitory effect on an EGFR-Del19/T790M/C797S kinase and cell proliferation of a KC-0122:Ba/F3EGFR-L858R/T790M/C797S three-mutation cell line and a KC-0116:Ba/F3EGFR-Del19/T790M/C797S three-mutation cell line.

Abstract: A traditional Chinese medicine composition for treating neuritis. The traditional Chinese medicine composition is prepared mainly from Notopterygii Rhizoma et Radix, Angelicae Pubescentis Radix, Poria, Saposhnikoviae Radix, Schizonepetae Herba, Chuanxiong Rhizoma, Platycodonis Radix, Bupleuri Radix, Peucedani Radix, Aurantii Fructus, and Glycyrrhizae Radix et Rhizoma. The traditional Chinese medicine composition can significantly relieve facial paralysis, movement disorders, and other related symptoms of facial neuritis in a rat, remarkably improve expression of VEGFb, VEGFR1, and VEGFR2 proteins in postoperative side facial nerves of the rat, and promote recovery and regeneration of damaged rear axons.

Abstract: Disclosed is a traditional Chinese medicinal composition for treating neurogenic pulmonary edema. The traditional Chinese medicinal composition is mainly prepared from Notopterygium root, angelicae pubescentis radix, poria cocos, radix saposhnikoviae, herba schizonepetae, rhizoma chuanxiong, platycodonis radix, radix bupleuri, common hogfennel root, fructus aurantii, and licorice root. The traditional Chinese medicinal composition can improve a lung index and lung wet weight/dry weight of a rat with neurogenic pulmonary edema, and has a therapeutic effect on the neurogenic pulmonary edema.

Abstract: A pharmaceutical composition for preventing or treating Alzheimer's disease and use thereof are disclosed and belong to the technical field of medicines. The pharmaceutical composition includes (Z)-3-(N-(3-bromo-4-fluorophenyl)-N?-hydroxyformamido)-4-(2-guanidinoethyl)amino)-1,2, 5-oxadiazole and anhydroicaritin. A pharmacodynamic experiment proves that the pharmaceutical composition achieves a synergistic therapeutic effect on treating Alzheimer's disease.

Abstract: The invention provided herein relates to methods and uses of a bispecific antibody, which specifically binds the surface antigen CD3 of immune cells and the BCMA antigen on the surface of tumor cells and which may bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing effects. The bispecific antibody may be used to mediate the T cell-specific killing of target cells in in vitro tests.

Abstract: A traditional Chinese medicinal composition is prepared from Herba schizonepetae, Radix saposhnikoviae, Notopterygium root, Radix angelicae pubescentis, Radix bupleuri, common hogfennel root, Rhizoma chuanxiong, Fructus aurantii, Poria cocos, Radix platycodonis, and liquorice root. The traditional Chinese medicinal composition can reduce the cough frequency of a guinea pig model with cough variant asthma, a percentage of eosinophils in a bronchoalveolar lavage fluid, and a level of serum eosinophil cationic proteins, and has a prevention and treatment effect on the cough variant asthma.

Abstract: The invention provided herein relates to methods and uses of a bispecific antibody, which specifically binds the surface antigen CD3 of immune cells and the BCMA antigen on the surface of tumor cells and which may bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing effects. The bispecific antibody may be used to mediate the T cell-specific killing of target cells in in vitro tests.

Abstract: A bispecific antibody, which specifically binds the surface antigen CD3 of immune cells and the BCMA antigen on the surface of tumor cells and which may bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing effects. The bispecific antibody may be used to mediate the T cell-specific killing of target cells in in vitro tests. The method for constructing a bispecific antibody is simple, and avoids the possibility of mismatching between two sets of light chains and heavy chains of a heterologous bispecific antibody, thus the difficulty of antibody purification is reduced, the affinity of the obtained antibody is high, the side effects of induced cytokines are few, and safety is high.

Abstract: Disclosed are a compound represented by the general Formula (I), or a stereisomer, tautomer, derivative, prodrug or pharmaceutically acceptable salt thereof, and a method for preparing the compound and use of the compound in manufacture of a medicament for treating a neuropathic pain and/or neuropathic pain syndrome or a medicament for combating an inflammation: wherein R1 is selected from hydrogen, halogen, alkyl, cyano and haloalkyl, R2 and R3 are independently selected from hydrogen, halogen, alkyl, haloalkyl and nitro, and R1, R2 and R3 are not hydrogen at the same time; furthermore, when either R2 or R3 is nitro or halogen, the other two of R1, R2 and R3 are not hydrogen at the same time. The compound has good effects in treating a neuropathic pain and/or neuropathic pain syndrome and good effects in combating an inflammation, and has not side effects such as addiction.

Abstract: The present disclosure provides use of icaritin in preparing a drug for preventing and treating a bleeding disorder and belongs to the field of medicine. The icaritin can relieve platelet dysfunction, shorten thromboplastin time, and promote blood coagulation, and can be used for preventing and treating the bleeding disorder, especially for treating hemorrhagic transformation after cerebral infarction, gastrointestinal bleeding caused by a thrombolytic or antithrombotic drug for cerebral infarction, or a bleeding complication of a thrombolytic or antithrombotic drug for myocardial infarction.

Abstract: The present invention belongs to the field of medicine, and relates to a compound of Formula I and a pharmaceutically acceptable salt thereof for using as a MAGL inhibitor, as well as a preparation method and use thereof, and an intermediate for preparing the same.

Abstract: The present invention relates to the fields of medicinal chemistry and pharmacotherapeutics, and in particular to a 2-cyano-3,12-dioxoolean-1,9(11)-dien-17-phenylacrylamide derivative and a preparation method thereof; and the present invention further relates to use of the novel compound in the preparation of an anticancer medicament.

Abstract: The present invention provides a multi-targeting fusion protein that blocks the growth of vascular endothelial cells and activates T cells, which comprises (i) a vascular endothelial cell growth inhibitory domain; (ii) an immunoglobulin Fc domain; and (iii) CD80 extracellular domain (ECD). The present invention also provides a polynucleotide encoding the multi-targeting fusion protein, a vector containing the polynucleotide, a host cell comprising the polynucleotide or the vector, and pharmaceutical composition comprising the multi-targeting fusion protein and an anti-PD-1 antibody. The multi-targeting fusion protein and pharmaceutical composition of the present invention can treat or prevent cancerous diseases in individuals.

Abstract: Provided is a tetravalent, homodimer-type bispecific antibody molecule that targets both immune effector cell antigen CD3 and tumor-related antigen CD19. The bispecific antibody molecule comprises first and second single-chain Fv and Fc fragments in sequence from the N-terminus to the C-terminus, wherein the first single-chain Fv can specifically bind to CD19, the second single-chain Fv can specifically bind to CD3, the first and second single-chains Fv are connected by means of a linker peptide, the second single-chain Fv and Fc fragments are directly connected to each other or connected by means of a linker peptide; and the Fc fragment does not have effector functions such as CDC, ADCC, and ADCP.

Abstract: Disclosed are a compound represented by the general Formula (I), or a stereisomer, tautomer, derivative, prodrug or pharmaceutically acceptable salt thereof, and a method for preparing the compound and use of the compound in manufacture of a medicament for treating a neuropathic pain and/or neuropathic pain syndrome or a medicament for combating an inflammation: wherein R1 is selected from hydrogen, halogen, alkyl, cyano and haloalkyl, R2 and R3 are independently selected from hydrogen, halogen, alkyl, haloalkyl and nitro, and R1, R2 and R3 are not hydrogen at the same time; furthermore, when either R2 or R3 is nitro or halogen, the other two of R1, R2 and R3 are not hydrogen at the same time. The compound has good effects in treating a neuropathic pain and/or neuropathic pain syndrome and good effects in combating an inflammation, and has not side effects such as addiction.

Abstract: The present invention relates to the field of medicines, and in particular to an imino-urea derivative containing a furan structure and a composition thereof. The derivative and the composition thereof can be used in the manufacture of a medicament for treating a disease pathologically characterized by indoleamine 2,3-dioxygenase-mediated tryptophan metabolic pathway. The present invention also relates to a method for preparing the derivative and an intermediate thereof.